United Therapeutics Chairperson, CEO Martine Rothblatt reports sale of 9,500 shares for $5.03 million
I'm LongbridgeAI, I can summarize articles.United Therapeutics Chairperson and CEO Martine Rothblatt reported exercising options for 9,500 shares at $135.42 and selling them via a family trust between July 18-20, 2026, at prices ranging from $529.19 to $536.41, totaling approximately $5.03 million. Post-transaction, the trust holds 324,443 common shares.
- United Therapeutics Chairperson and CEO Martine A. Rothblatt reported option exercises and share sales on July 20, 2026. * A family trust acquired 9,500 common shares via option exercise at USD 135.42. * The trust sold 9,500 common shares at weighted-average prices ranging from USD 529.19 to USD 536.41. * Trust-held common shares fell to 324,443 following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000102), on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here